Australia markets closed

Anavex Life Sciences Corp. (AVXL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.3700-0.0800 (-1.80%)
As of 10:45AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.4500
Open4.4000
Bid4.3400 x 400
Ask4.4000 x 200
Day's range4.3500 - 4.4662
52-week range4.1700 - 10.4500
Volume129,175
Avg. volume1,244,622
Market cap358.832M
Beta (5Y monthly)0.58
PE ratio (TTM)N/A
EPS (TTM)-0.5400
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est34.67
  • GlobeNewswire

    Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

    NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conferen

  • GlobeNewswire

    Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

    NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April

  • GlobeNewswire

    Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia

    First patient screened ahead of schedule Trial to investigate positive, negative, and cognitive domains of schizophrenia ANAVEX®3-71’s differentiated dual novel mechanism of action offers the potential to synergistically activate both SIGMAR1 and M1 muscarinic receptors and treat all symptom domains of schizophrenia without the side effects of standard of care antipsychotics NEW YORK, March 18, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clin